Stevanato Group (NYSE:STVN) Bolsa

Stevanato Group

Stevanato Gr

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

ABNB

BLAC

BSLK

CNSP

FFIE

INFA

JRSH

MBRX

MYNA

PCLA

SLSR

STAI

STVN

VRPX

ZCAR

Airbnb supera expectativas de ingresos y sus acciones suben un 13,9% en premercado. Descubre qué otros valores están destacando hoy.

Acciones de Airbnb (ABNB) suben alrededor del 14%; 20 acciones que se mueven en el premercado de EE.UU.

Stevanato Group SpA

Baird analyst Ghansham Panjabi maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Neutral and raises the price target from $105 to $110.

News

Price Target

Analyst Ratings

Baird Maintains Neutral on Crown Holdings, Raises Price Target to $110

Baird analyst Robert Mason maintains Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) with a Neutral and raises the price target from $216 to $219.

Baird Maintains Neutral on Badger Meter, Raises Price Target to $219

Barclays analyst Brendan Lynch maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Overweight and raises the price target from $113 to $117.

Barclays Maintains Overweight on Crown Castle, Raises Price Target to $117

NNVC

NanoViricides Intends To File For Orphan Drug Status For Several Indications Of NV-387, Including MPox, Smallpox, And Measles

Baird analyst Eric Coldwell maintains Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Neutral and raises the price target from $313 to $490.

MEDP

Baird Maintains Neutral on Medpace Hldgs, Raises Price Target to $490

WIIM

DTIL

DTIL stock has given up its prior gain. Precision BioSciences shares were trading higher after the company was granted FDA orphan drug designation for PBGENE-DMD in Duchenne muscular dystrophy.

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant">https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant</a>

Biotech

Government

Regulations

General

'European Commission Approves IMBRUVICA (ibrutinib) As The First Targeted Therapy For Patients With Previously Untreated Mantle Cell Lymphoma Who Would Be Eligible For Autologous Stem Cell Transplant' - Johnson & Johnson

NanoViricides, Inc., a publicly traded company (NYSE Amer.:<a href="https://pr.report/ckhj">NNVC</a> ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio. The Company further elucidates that the MPox, Smallpox, and Measles indications of NV-387 are expected to enable rapid regulatory development towards approval and realization of early revenues from multiple pathways.
As additional indications of NV-387 have been validated in animal studies, approvals against the multiple indications of NV-387 are expected to drive increase in overall market share that the Company can achieve once the drug is approved. The costs leading up to Phase II clinical trial would be substantially common across all indications of this same drug, improving return on investment significantly.
Additionally, NV-387 should become the drug of choice to develop and stockpile for strategic pandemic preparedness and response because of its activity against most of the viruses of concern at present: Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles. The Company believes that NV-387 is likely to be effective against Ebola/Marburg viruses, Hendra/Nipah viruses, and other lethal viruses as well, based on known binding of these viruses to HSPG. In addition to the USA, UK, Europe and India have established agencies to enable pandemic preparedness and response.
Approval of NV-387 against any of the currently established indications would drive its value as a strategic tool for pandemic preparedness against a multiplicity of potential threats. Pandemic preparedness is already a multi-billlion dollar market globally, and growing, as additional countries and regions seek to fortify their public health defenses against unknown viral threats. (see further below).
To this end, the Company is moving forward to open a Phase II clinical trial to evaluate effectiveness of NV-387 to treat MPox virus infections. If the trial is successful, NV-387 will be the first ever drug to be approved for MPox [1] . There is no effective drug for MPox at present.
Such approval will also translate to NV-387 as a currently best available option for potential smallpox therapeutics as well, based on human infection data of the smallpoxvirus-related virus MPXV , rather than animal orthopoxvirus data that FDA has currently relied upon [1] .
Additionally, the Company intends to file for orphan drug status for several indications of NV-387, including MPox, Smallpox, and Measles. Each orphan drug indication in itself would result in several economic benefits, in addition to increased interactions with the FDA.
We believe some of the indications of NV-387 will be eligible for Fast-Track designation, as well as for awards of Priority Review Vouchers (PRV). A PRV is a tradable instrument that has been traded at about $150 million to $250 million dollars each because the buying pharma company can apply the PRV for any one drug to expedite its own drugs in development. Thus PRVs could enable an early revenue source for the Company if awarded.
The speed with which a first indication of NV-387 can be approved is estimated to be the fastest for Mpox, Smallpox, and Measles. This is because of the specific orphan drug characteristics of these diseases in the USA. This is why the Company has prioritized these indications.
The Company is continuing its work on planning of clinical trials for what are generally considered as commercially lucrative indications that include Influenza, RSV, other respiratory viruses, as well as coronaviruses.
Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses [2] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.
To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.
Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.
NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

NanoViricides Highlights Broad Antiviral Effectiveness Of NV-387; Expects Accelerated Development And Early Revenues From MPox, Smallpox, And Measles Indications

Barclays analyst Brandon Oglenski maintains Canadian National Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) with a Equal-Weight and lowers the price target from $106 to $99.

Barclays Maintains Equal-Weight on Canadian National Railway, Lowers Price Target to $99

Baird analyst Eric Coldwell maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Neutral and raises the price target from $159 to $196.

Baird Maintains Neutral on IQVIA Hldgs, Raises Price Target to $196

Contracts

LAKE

Lakeland Fire + Safety's Jolly Scarpe Brand Ships $3.1M  Fire Boot Order With Italian Government

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma">https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma</a>

'European Commission Approves DARZALEX As The First Licensed Treatment For Patients With High-Risk Smouldering Multiple Myeloma" - Johnson & Johnson

Rebel Light Beer Early Adoption and Strong Sales Performance from Independents Retailers Validates Brand Strategy, Signals Continued Accelerated Growth, and Positions Brand for Regional and National Retail Chain Expansion During Critical Shelf Review Period
Nashville, TN, July 23, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) ("American Rebel" or the "Company"), a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (<a href="https://www.globenewswire.com/Tracker?data=6IFUR3-nu21ZhOj9sEQRwPkZBqUu6Ls-wL_HqDhRtO_S2Yi1rnHeK76I2Y7fchTBIj5IC53hXkYsmsXJcowVqS3cYz0Vnp3uFy5IFvZMYKrg-kn4FupvT1TOnrM3nbgmBaRXBiPZVWbaqryeBKMQnjfHv1ptgYv3D_P7eRCLEz45Qklb__wBCfnk49SwQbHIQRX9c_QVJ-_9XApT63jMRnL1i6xrzAXHdBYi8DnR_2hASepk8VLARKogiosGbUGmuxw_0QGq32XKVrdES-CyKA==">americanrebel.com</a>) and the creator of American Rebel Light Beer (<a href="https://www.globenewswire.com/Tracker?data=6IFUR3-nu21ZhOj9sEQRwDg3yeT13tHdh6Iip0tur4akrBWQaMIgm4l10jur_a8Fnu50pfKXJQXolrKcv0B2iO3vumZM0ZTjeObIAPClbEAmyL3Xszj6Klohcatv26IdKmTXT1a_4HXHH4HDWxd2h_WyEJShF9G7u19NaK6raO2c6X2jF5cYX1HhmphsFGFJ-nKfcP43bDQJAxnGk8Cs1VuaNK2XPziu3nvFedbqDG_3gMbuBwWk40ecdYCk1jW-BJe_o7c1-x-6wZfnycanO1cHUpdQviNHmNE8C7-ah0g=">americanrebelbeer.com</a>) - America's Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, Stand Your Ground Beer - continues its strategic retail expansion by announcing extraordinary performance across the independent class of trade.
Patriotism Meets Performance: 1,100+ New Independent Accounts Signal Rebel Light Beer Momentum
This strategically vital channel (Independent Accounts) now drives 57% of total sales and accounts for 80% of American Rebel Light Beer's national distribution footprint, validating the company's grassroots-first retail strategy and deep connection to local markets. Independent retailers aren't just selling the brand—they're amplifying its Patriotic mission, ethos, and authenticity across every shelf and aisle. In the past five months alone, American Rebel secured over 1,100 new independent accounts, averaging 200+ new placements monthly, which underscores the brand's alignment with communities that share its values.
These accounts aren't passive participants; they're active brand builders. Through in-store promotions, consumer sampling activations, and boots-on-the-ground engagement, they've helped drive repeat purchases, regional awareness, and consistent sales velocity. It's a relationship forged in loyalty and purpose—not just placement.
Event Exposure Converts to Shelf Space as Consumers Push for Local Availability – Fan's Demand it, Retailers are Listening.
The momentum behind American Rebel Light Beer now extends far beyond independent retail—it's being supercharged through high-profile brand activations and national visibility platforms. These include title sponsorships at premier NHRA events, flagship partnerships through TSR Nitro with motorsports legends Tony Stewart and four-time NHRA Funny Car World Champion Matt Hagan, and dynamic account activation at top-tier venues in Nashville. From Kid Rock's Big Ass Honky Tonk to Tootsie's, Rippy's, Honky Tonk Central, and a full-scale takeover at the iconic Loser's Midtown, American Rebel is earning prime placement in locations that attract high-volume consumer traffic and cultural influence. These experiential touchpoints aren't just building awareness—they're igniting organic demand. Across regional markets, fans who encounter the brand at these events and venues are returning home and asking local retailers to stock American Rebel Light Beer—creating actionable retail pressure and accelerating expansion.

AREB

American Rebel Light Beer Gains 1,100+ Independent Retailers, Driving 57% Of Sales And Fueling National Expansion

Benchmark analyst Matthew Harrigan maintains Grupo Televisa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TV#NYSE">TV</a>) with a Buy and raises the price target from $7 to $9.

Benchmark Maintains Buy on Grupo Televisa, Raises Price Target to $9

Financing

Offerings

METC

Ramaco Resources Announces Proposed Offering Of Senior Unsecured Notes Due 2030, Intends To Use Net Proceeds To Redeem All Outstanding Senior Unsecured Notes Due 2026

Social Security has become a make-or-break income source for a swelling share of Americans even as the program barrels toward insolvency, an anniversary survey by AARP warns.
What Happened: Two-thirds of today's retirees now <a href="https://www.aarp.org/pri/topics/work-finances-retirement/social-security/social-security-90th-anniversary-survey/?CMP=RDRCT-PRI-SOCSEC">say</a> they &#8220;rely substantially&#8221; on their monthly benefit, up from about half in 2005, and 78% of adults fear the checks won't cover basic living costs.
66% of retirees and 63% of workers not yet retired expect Social Security to be their largest income source, the survey shows. Only 36% believe the system will keep paying full benefits when they need them, down seven points since 2020.
96% call the program important, yet 78% doubt its adequacy as pessimism peaks among Americans in their 30s. The survey shows that knowledge gaps exist as well. Just 24% correctly picked age 70 as the point to maximize monthly checks, and one-third wrongly assume the program would vanish if its trust funds are empty.
&#8220;We&#8217;re concerned that faith in the system &#8230; is waning,&#8221; AARP CEO Myechia Minter-Jordan <a href="https://www.cbsnews.com/news/social-security-aarp-study-retirement-income-90th-anniversary/">said</a> in a call with CBS. &#8220;We&#8217;re concerned about their confidence that they will be able to receive benefits that they have paid into over time.&#8221;
See Also: <a href="https://www.benzinga.com/news/entertainment/25/07/46567809/stephen-colbert-blasts-donald-trumps-social-media-post-celebrating-late-show-cancellation-warns-they-made-one-mistake">Stephen Colbert Blasts Donald Trump&#8217;s Social Media Post Celebrating Late Show Cancellation, Warns &#8216;They Made One Mistake&#8217;</a>
Why It Matters: Trustees project the combined retirement and disability funds will deplete in 2034, triggering a 20% across-the-board cut. Beneficiaries have already ballooned to roughly 68 million, a record that is <a href="https://states.aarp.org/idaho/new-aarp-survey-shows-confidence-in-the-future-of-social-security-among-younger-adults-at-15-year-low">forecast</a> to hit 82 million by 2035.
Record claiming this year coincides with plans to trim 7,000 Social Security staff, <a href="https://www.benzinga.com/25/05/45446292/previous-acting-ssa-commissioner-slams-media-hysteria-says-trump-is-saving-social-security-is-he-right">the deepest reduction</a> in decades, raising service-delay fears. Wealth inequality compounds the pressure, with about half of private-sector workers lacking a retirement plan, Pew research finds.
Lawmakers face choices ranging from taxing higher wages to lifting the retirement age. A report from earlier in the year noted that the 2025 payroll-tax cap of $176,100 means billionaires like Elon Musk <a href="https://www.benzinga.com/news/25/01/42821537/15-minutes-into-2025-elon-musk-was-done-with-social-security-tax-meanwhile-94-of-americans-take-the-entire-year">finish paying the levy</a> "15 minutes" into the year, fueling calls to scrap the cap entirely.
Meanwhile, more analysis predicts a potentially record <a href="https://www.benzinga.com/personal-finance/25/04/45110258/the-2026-social-security-cola-could-be-the-biggest-in-years-but-inflation-could-still-outpace-your-benefits">cost-of-living adjustment in 2026</a>, but warns even a big raise may lag inflation if Congress fails to shore up the fund.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46568764/obama-slams-trumps-coup-allegations-over-2016-election-as-outrageous-and-ridiculous-in-rare-public-rebuke">Obama Slams Trump&#8217;s &#8216;Coup&#8217; Allegations Over 2016 Election As &#8216;Outrageous&#8217; And &#8216;Ridiculous&#8217; In Rare Public Rebuke</a></li>
</ul>
Image Via Shutterstock

Personal Finance

78% Americans Fear Their Social Security Won't Stretch Far Enough, AARP Survey Finds As Trust Fund's Clock Ticks Down

XBIO

Xenetic Biosciences Expands R&D Collaboration With Scripps Research Institute To Advance The DNase Platform

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended not buying United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>). He added, &#8220;UPS is a real quandary. I love that yield, but I do think that the fundamentals are still hurting. I'm going to <a href="https://www.benzinga.com/quote/UPS/earnings">have to take a pass on that one.&#8221;</a>
On the earnings front, UPS will release second-quarter results on Tuesday, July 29. Analysts expect the company to report quarterly earnings at $1.57 per share, down from $1.79 per share in the year-ago period. UPS projects quarterly revenue of $20.85 billion, compared to $21.82 billion a year earlier.
Cramer said he would be a little careful with SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>).
See Also: <a href="https://www.benzinga.com/news/25/07/46542083/jim-cramer-coffee-chain-general-mills">Jim Cramer Says This Coffee Chain Is &#8216;The Way To Go&#8217; But General Mills? &#8216;That&#8217;s A Tough One&#8217;</a>
Piper Sandler analyst James Fish, on July 14, downgraded SoundHound AI from Overweight to Neutral and maintained the price target of $12.
&#8220;Modine (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has got a lot of good things going,&#8221; Cramer said. &#8220;I think Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) is a better play for you than Modine.&#8221;
Modine announced that it will host a conference call and webcast to discuss its first quarter financial results on Thursday, July 31, 2025.
Cramer recommended not buying Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) right here, saying, &#8220;ETR's had such a run, I know it can go higher.&#8221;
As per the recent news, Entergy, on July 1, said it has completed the sale of its natural gas distribution business to Delta Utilities.
Price Action:
<ul class="wp-block-list">
<li>UPS shares gained 2.3% to settle at $101.14 on Tuesday.</li>
<li>SoundHound shares fell 3.1% to close at $11.34.</li>
<li>Modine shares gained 0.1% to settle at $93.83 on Tuesday.</li>
<li>Entergy shares gained 1.7% to close at $88.53.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46541326/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

SOUN

Jim Cramer Loves 'That Yield' But Passes On This Stock: 'Fundamentals Are Hurting'

Benchmark analyst Mark Zgutowicz maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $640 to $800.

Benchmark Maintains Buy on Meta Platforms, Raises Price Target to $800

Alpha Modus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>), an innovator in AI-driven retail solutions, today announced a landmark agreement with CashXAI, Inc. and CashX, LLC, granting Alpha Modus exclusive nationwide licensing rights to deploy and monetize all CashX kiosks and mobile applications across the U.S.—superseding all prior deals.
This sweeping agreement empowers Alpha Modus as the sole fulfillment arm for all of CashX's existing and future contracts in the U.S.—unlocking a rapid-deployment pipeline and opportunities spanning up to 20,000 U.S. locations over the next 3 to 5 years and representing over $20 million in monthly recurring revenue potential at full scale.
"This is a game-changing moment," said Chris Chumas, Chief Sales Officer of Alpha Modus. "This exclusive license allows us to execute at scale—potentially delivering vital financial services to the 60 million+ underbanked households in America with speed, reach, and efficiency." Chumas continued, "The CashX kiosk will now serve as the centerpiece of our partner ecosystem, enabling us to further develop and integrate our patented retail technologies alongside other innovative retail solutions."
Highlights of the agreement include:
- Full exclusivity across the U.S. to deploy and operate all CashX kiosk and mobile technologies
- Perpetual license to CashX's core intellectual property, with the option to expand globally within 18 months
- Integration of Alpha Modus's AI patents to enhance analytics, ad targeting, and revenue generation
- Takeover of existing CashX contracts across thousands of locations
- Capital commitment by Alpha Modus up to $2 million to accelerate nationwide rollout

AMOD

Alpha Modus Secures Exclusive U.S. Rights To CashX Kiosks, Targeting 20K Locations And $20M Monthly Revenue Potential

Press Releases

Stevanato Group to Present at Upcoming Investor Conferences

Stevanato Group to Present at Upcoming Investor Conference

Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025

Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025

Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025

Stevanato Group to Participate in Upcoming Investor Conferences

Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Stevanato Group

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL